Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland

L. Tilson; M. Jit; S. Schmitz; C. Walsh; P. Garvey; P. McKeown; M. Barry

doi:10.1016/j.vaccine.2011.07.056

Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland

L. Tilson^*, M. Jit, S. Schmitz, C. Walsh, P. Garvey, P. McKeown, M. Barry

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

26 Citations (Scopus)

Abstract

We evaluated the cost-effectiveness of universal infant rotavirus (RV) vaccination compared to current standard of care of "no vaccination". Two RV vaccines are currently licensed in Ireland: Rotarix™ and RotaTeq™. A cohort model used in several European countries was adapted using Irish epidemiological, resource utilisation and cost data. The base case model considers the impact of Rotarix vaccination on health-related quality of life of children under five years old from a healthcare payer perspective. Other scenarios explored the use of RotaTeq, impact on one caregiver, on societal costs and on cases that do not seek medical attention. Cost was varied between the vaccine list price (€100/course) in the base case and an assumed tender price (€70/course). One-way and probabilistic sensitivity analyses were conducted. Implementing universal RV vaccination may prevent around 1970 GP visits, 3280 A&E attendances and 2490 hospitalisations. A vaccination programme was estimated to cost approximately €6.54 million per year but €4.65 million of this would be offset by reducing healthcare resource use. The baseline ICER was €112,048/QALY and €72,736/QALY from the healthcare payer and societal perspective, respectively, falling to €68,896 and €43,916/QALY, respectively, if the impact on one caregiver was considered. If the price fell to €70 per course, universal RV vaccination would be cost saving under all scenarios. Results were sensitive to vaccination costs, incidence of RV infection and direct medical costs. Universal RV vaccination would not be cost-effective under base case assumptions. However, it could be cost-effective at a lower vaccine price or from a wider societal perspective.

Original language	English
Pages (from-to)	7463-7473
Number of pages	11
Journal	Vaccine
Volume	29
Issue number	43
DOIs	https://doi.org/10.1016/j.vaccine.2011.07.056
Publication status	Published - 6 Oct 2011

Bibliographical note

Funding Information:
This paper formed part of an independent report commissioned and funded by the National Immunisation Advisory Committee (NIAC) . The authors would like to thank the members of NIAC for their advice and contribution to the report. The views expressed are not necessarily those of NIAC. We also wish to thank the staff working at Health Atlas (Health Service Executive), the National Immunisation Office and the Health Protection Surveillance Centre for providing data inputs for this study.

Keywords

Cost-effectiveness
Rotavirus
Vaccination

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2011.07.056

Cite this

@article{b23958a838a545f1b75389ba0d6df774,

title = "Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland",

abstract = "We evaluated the cost-effectiveness of universal infant rotavirus (RV) vaccination compared to current standard of care of {"}no vaccination{"}. Two RV vaccines are currently licensed in Ireland: Rotarix{\texttrademark} and RotaTeq{\texttrademark}. A cohort model used in several European countries was adapted using Irish epidemiological, resource utilisation and cost data. The base case model considers the impact of Rotarix vaccination on health-related quality of life of children under five years old from a healthcare payer perspective. Other scenarios explored the use of RotaTeq, impact on one caregiver, on societal costs and on cases that do not seek medical attention. Cost was varied between the vaccine list price (€100/course) in the base case and an assumed tender price (€70/course). One-way and probabilistic sensitivity analyses were conducted. Implementing universal RV vaccination may prevent around 1970 GP visits, 3280 A&E attendances and 2490 hospitalisations. A vaccination programme was estimated to cost approximately €6.54 million per year but €4.65 million of this would be offset by reducing healthcare resource use. The baseline ICER was €112,048/QALY and €72,736/QALY from the healthcare payer and societal perspective, respectively, falling to €68,896 and €43,916/QALY, respectively, if the impact on one caregiver was considered. If the price fell to €70 per course, universal RV vaccination would be cost saving under all scenarios. Results were sensitive to vaccination costs, incidence of RV infection and direct medical costs. Universal RV vaccination would not be cost-effective under base case assumptions. However, it could be cost-effective at a lower vaccine price or from a wider societal perspective.",

keywords = "Cost-effectiveness, Rotavirus, Vaccination",

author = "L. Tilson and M. Jit and S. Schmitz and C. Walsh and P. Garvey and P. McKeown and M. Barry",

note = "Funding Information: This paper formed part of an independent report commissioned and funded by the National Immunisation Advisory Committee (NIAC) . The authors would like to thank the members of NIAC for their advice and contribution to the report. The views expressed are not necessarily those of NIAC. We also wish to thank the staff working at Health Atlas (Health Service Executive), the National Immunisation Office and the Health Protection Surveillance Centre for providing data inputs for this study. ",

year = "2011",

month = oct,

day = "6",

doi = "10.1016/j.vaccine.2011.07.056",

language = "English",

volume = "29",

pages = "7463--7473",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier",

number = "43",

}

TY - JOUR

T1 - Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland

AU - Tilson, L.

AU - Jit, M.

AU - Schmitz, S.

AU - Walsh, C.

AU - Garvey, P.

AU - McKeown, P.

AU - Barry, M.

N1 - Funding Information: This paper formed part of an independent report commissioned and funded by the National Immunisation Advisory Committee (NIAC) . The authors would like to thank the members of NIAC for their advice and contribution to the report. The views expressed are not necessarily those of NIAC. We also wish to thank the staff working at Health Atlas (Health Service Executive), the National Immunisation Office and the Health Protection Surveillance Centre for providing data inputs for this study.

PY - 2011/10/6

Y1 - 2011/10/6

N2 - We evaluated the cost-effectiveness of universal infant rotavirus (RV) vaccination compared to current standard of care of "no vaccination". Two RV vaccines are currently licensed in Ireland: Rotarix™ and RotaTeq™. A cohort model used in several European countries was adapted using Irish epidemiological, resource utilisation and cost data. The base case model considers the impact of Rotarix vaccination on health-related quality of life of children under five years old from a healthcare payer perspective. Other scenarios explored the use of RotaTeq, impact on one caregiver, on societal costs and on cases that do not seek medical attention. Cost was varied between the vaccine list price (€100/course) in the base case and an assumed tender price (€70/course). One-way and probabilistic sensitivity analyses were conducted. Implementing universal RV vaccination may prevent around 1970 GP visits, 3280 A&E attendances and 2490 hospitalisations. A vaccination programme was estimated to cost approximately €6.54 million per year but €4.65 million of this would be offset by reducing healthcare resource use. The baseline ICER was €112,048/QALY and €72,736/QALY from the healthcare payer and societal perspective, respectively, falling to €68,896 and €43,916/QALY, respectively, if the impact on one caregiver was considered. If the price fell to €70 per course, universal RV vaccination would be cost saving under all scenarios. Results were sensitive to vaccination costs, incidence of RV infection and direct medical costs. Universal RV vaccination would not be cost-effective under base case assumptions. However, it could be cost-effective at a lower vaccine price or from a wider societal perspective.

AB - We evaluated the cost-effectiveness of universal infant rotavirus (RV) vaccination compared to current standard of care of "no vaccination". Two RV vaccines are currently licensed in Ireland: Rotarix™ and RotaTeq™. A cohort model used in several European countries was adapted using Irish epidemiological, resource utilisation and cost data. The base case model considers the impact of Rotarix vaccination on health-related quality of life of children under five years old from a healthcare payer perspective. Other scenarios explored the use of RotaTeq, impact on one caregiver, on societal costs and on cases that do not seek medical attention. Cost was varied between the vaccine list price (€100/course) in the base case and an assumed tender price (€70/course). One-way and probabilistic sensitivity analyses were conducted. Implementing universal RV vaccination may prevent around 1970 GP visits, 3280 A&E attendances and 2490 hospitalisations. A vaccination programme was estimated to cost approximately €6.54 million per year but €4.65 million of this would be offset by reducing healthcare resource use. The baseline ICER was €112,048/QALY and €72,736/QALY from the healthcare payer and societal perspective, respectively, falling to €68,896 and €43,916/QALY, respectively, if the impact on one caregiver was considered. If the price fell to €70 per course, universal RV vaccination would be cost saving under all scenarios. Results were sensitive to vaccination costs, incidence of RV infection and direct medical costs. Universal RV vaccination would not be cost-effective under base case assumptions. However, it could be cost-effective at a lower vaccine price or from a wider societal perspective.

KW - Cost-effectiveness

KW - Rotavirus

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=80053452979&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2011.07.056

DO - 10.1016/j.vaccine.2011.07.056

M3 - Article

C2 - 21821085

AN - SCOPUS:80053452979

VL - 29

SP - 7463

EP - 7473

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 43

ER -

Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this